Live Poll Results — Which orphan drug made headlines in 2019 when its manufacturer set a $2.1 millio
See real-time poll results. Powered by AIPolls.Net.
Pharmaceutical Pricing Strategies: The Orphan Drug Revolution
The pharmaceutical industry employs various pricing strategies, but perhaps none more controversial than those for orphan drugs - medications developed for rare diseases affecting fewer than 200,000 people. These treatments often come with eye-watering price tags justified by R&D costs and limited patient populations. This poll tests your knowledge about a landmark orphan drug pricing case that changed industry practices.
Which orphan drug made headlines in 2019 when its manufacturer set a $2.1 million price tag, making it the most expensive treatment in the world at that time?
Poll Type: Trivia | Total Votes: 0
| Option | Votes | Percentage |
|---|---|---|
| {'choice_text': 'Zolgensma (onasemnogene abeparvovec) - Novartis gene therapy for spinal muscular atrophy', 'is_correct': True} | 0 | 0% |
| {'choice_text': 'Soliris (eculizumab) - Alexion treatment for paroxysmal nocturnal hemoglobinuria', 'is_correct': False} | 0 | 0% |
| {'choice_text': 'Ravicti (glycerol phenylbutyrate) - Horizon Therapeutics medication for urea cycle disorders', 'is_correct': False} | 0 | 0% |
| {'choice_text': 'Actimmune (interferon gamma-1b) - Horizon Therapeutics treatment for chronic granulomatous disease', 'is_correct': False} | 0 | 0% |